$CBDW -- Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. https://finance.yahoo.com/news/1606-corp-target-strategic-investment-130000778.html